Literature DB >> 16409145

Prostatitis/chronic pelvic pain syndrome.

Geoffrey M Habermacher1, Judd T Chason, Anthony J Schaeffer.   

Abstract

We review the diagnosis, categorization, and treatment of prostatitis/chronic pelvic pain syndrome based on the National Institutes of Health (NIH) classification. Prostatitis is an extremely common syndrome that afflicts 2%-10% of men. Formerly a purely clinical diagnosis, prostatitis is now classified within a complex series of syndromes (NIH category I-IV prostatitis) that vary widely in clinical presentation and response to treatment. Acute bacterial prostatitis (category I) and chronic bacterial prostatitis (category II) are characterized by uropathogenic infections of the prostate gland that respond well to antimicrobial treatment. In contrast, chronic prostatitis/chronic pelvic pain syndrome (category III), which accounts for 90%-95% of prostatitis cases, is of unknown etiology and is marked by a mixture of pain, urinary, and ejaculatory symptoms with no uniformly effective therapy. Asymptomatic inflammatory prostatitis (category IV) is an incidental finding of unknown clinical significance. This review describes the current status of prostatitis syndromes and explores the future prospects of new diagnostic tools and therapies.

Entities:  

Mesh:

Year:  2006        PMID: 16409145     DOI: 10.1146/annurev.med.57.011205.135654

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  42 in total

1.  Survey of a pelvic health physiotherapy community of practice: a pilot study to gain member input to help sustain and advance the group.

Authors:  Jodi A Boucher; Donna L MacIntyre
Journal:  Physiother Can       Date:  2015       Impact factor: 1.037

2.  Physical activity and chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Ran Zhang; Andrea K Chomistek; Jordan D Dimitrakoff; Edward L Giovannucci; Walter C Willett; Bernard A Rosner; Kana Wu
Journal:  Med Sci Sports Exerc       Date:  2015-04       Impact factor: 5.411

Review 3.  The management of chronic prostatitis in men with HIV.

Authors:  Vincent M Santillo; Franklin C Lowe
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

4.  Histopathological classification criteria of rat model of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Xianjin Wang; Shan Zhong; Tianyuan Xu; Leilei Xia; Xiaohua Zhang; Zhaowei Zhu; Minguang Zhang; Zhoujun Shen
Journal:  Int Urol Nephrol       Date:  2014-11-20       Impact factor: 2.370

Review 5.  Chemokines and BPH/LUTS.

Authors:  Jill A Macoska
Journal:  Differentiation       Date:  2011-05-19       Impact factor: 3.880

6.  Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study.

Authors:  Megan D Fesinmeyer; Erika M Kwon; Rong Fu; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2011-02-25       Impact factor: 4.104

7.  Prostatic fibrosis is associated with lower urinary tract symptoms.

Authors:  Jinjin Ma; Mehrnaz Gharaee-Kermani; Lakshmi Kunju; John M Hollingsworth; Jeremy Adler; Ellen M Arruda; Jill A Macoska
Journal:  J Urol       Date:  2012-08-17       Impact factor: 7.450

8.  Longitudinal association between prostatitis and development of benign prostatic hyperplasia.

Authors:  Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; Michael M Lieber; Steven J Jacobsen
Journal:  Urology       Date:  2008-03       Impact factor: 2.649

9.  Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer.

Authors:  Yin Liu; Jun Qin Mo; Qiande Hu; Gregory Boivin; Linda Levin; Shan Lu; Dianer Yang; Zhongyun Dong; Shan Lu
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

10.  A novel murine model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by immunization with a spermine binding protein (p25) peptide.

Authors:  Cengiz Z Altuntas; Firouz Daneshgari; Elias Veizi; Kenan Izgi; Fuat Bicer; Ahmet Ozer; Kerry O Grimberg; Bakytzhan Bakhautdin; Cagri Sakalar; Cemal Tasdemir; Vincent K Tuohy
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-01-23       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.